Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fondaparinux. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINC1 known ✓ | P01008 | 2/20 | 0.79 |
| ▸ | F10 | P00742 | 5/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 0.79 |
| ▸ | HPSE | Q9Y251 | 12/20 | 0.73 |
| ▸ | PF4 | P02776 | 2/20 | 0.68 |
| ▸ | IFNG | P01579 | 1/20 | 0.65 |
| ▸ | BMP2 | P12643 | 1/20 | 0.65 |
| ▸ | CCL2 | P13500 | 1/20 | 0.65 |
| ▸ | VEGFA | P15692 | 1/20 | 0.65 |
| ▸ | SELP | P16109 | 1/20 | 0.65 |
| ▸ | BMP6 | P22004 | 1/20 | 0.65 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.65 |
| ▸ | CCL11 | P51671 | 1/20 | 0.65 |
| ▸ | WNT3A | P56704 | 1/20 | 0.65 |
| ▸ | SELPLG | Q14242 | 1/20 | 0.65 |
| ▸ | SHH | Q15465 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fondaparinux SCHEMBL1650579 | 0.79 | F10 (1.00) | F10F2SERPINC1HPSEPF4 | |
| Fondaparinux SCHEMBL15296579 | 0.79 | F10 (1.00) | F10F2SERPINC1HPSEPF4 | |
| Fondaparinux SCHEMBL19619397 | 0.79 | F10 (1.00) | F10F2SERPINC1HPSEPF4 | |
| Fondaparinux SCHEMBL17655218 | 0.79 | F10 (1.00) | F10F2SERPINC1HPSEPF4 | |
| Fondaparinux SCHEMBL14227800 | 0.79 | F10 (1.00) | F10F2SERPINC1HPSEPF4 | |
| SCHEMBL16688357 | 0.76 | F10 (0.81) | F10F2SERPINC1HPSEPF4 | |
| SCHEMBL16688383 | 0.76 | F10 (0.81) | F10F2SERPINC1HPSEPF4 | |
| SCHEMBL19618233 | 0.76 | F10 (0.81) | F10F2SERPINC1HPSEPF4 | |
| SCHEMBL16688342 | 0.76 | F10 (0.81) | F10F2SERPINC1HPSEPF4 | |
| SCHEMBL31087042 | 0.75 | BMP2 (0.61) | F10F2SERPINC1HPSEPF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14287 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12623010-B2 | Blood oxygenator with an organic membrane | UNIWERSYTET SLASKI (PL) | 2026-05-12 | — | — | US | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12605371-B2 | Combination therapy for cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724602-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING BLOOD CLOTS IN BIOLOGICAL SAMPLES | 10X Genomics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260097063-A1 | ANTI-C5 ANTIBODY/C5 IRNA DOSING REGIMENS FOR TREATING C5-ASSOCIATED DISEASES | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | claimed |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | EPIZON PHARMA INC (US) | 2026-03-26 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-12553905-B2 | Devices and methods for plasma separation and metering | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2026-02-17 | — | — | US | claimed |
| US-12539311-B2 | Short-acting heparin-based anticoagulant compounds and methods | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-02-03 | — | — | US | claimed |
| WO-2004019909-A2 | BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING CARDIOVASCULAR OR RENAL DRUGS | NOVADEL PHARMA INC. (US) | 2004-03-11 | — | — | WO | claimed |
| WO-2003090696-A2 | METHODS AND PRODUCTS FOR MUCOSAL DELIVERY | MOMENTA PHARMACEUTICALS, INC. (US) | 2003-11-06 | — | — | WO | claimed |
| US-20030203385-A1 | Monitoring heterogeneous populations of therapeutic heparin products for effectiveness in treating blood, nervous, inflammatory , kidney, nervous system, respiratory and autoimmune diseases | MOMENTA PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | claimed |
| WO-2003078960-A2 | ANALYSIS OF SULFATED POLYSACCHARIDES | MOMENTA PHARMACEUTICALS, INC. (US) | 2003-09-25 | — | — | WO | claimed |
| US-20030078517-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2003-04-24 | — | — | US | claimed |
| US-20030077229-A1 | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs | NOVADEL PHARMA INC. | 2003-04-24 | — | — | US | claimed |
| WO-2002079778-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| US-20020061835-A1 | Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream | RHEOLOGICS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |